Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate SecretaryGlobeNewsWire • 09/03/25
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/11/25
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/11/25
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/30/25
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 DegradersBusiness Wire • 06/25/25
Kymera Stock Gains on Positive Data on Investigational Dermatitis DrugZacks Investment Research • 06/03/25
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 DegraderGlobeNewsWire • 06/02/25
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025GlobeNewsWire • 05/30/25
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International ConferenceGlobeNewsWire • 05/19/25